

## Lydia Crowe

1. Tremblay G, Livings C, Crowe L, Kapetanakis V, Briggs A. Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. *Clinicoecon Outcomes Res.* 2016;8:323-33.
2. Treharne C, Crowe L, Booth D, Ihara Z. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. *Eur Urol Focus.* 2016.
3. Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. *Pharmacoeconomics.* 2016;34(7):709-21.
4. Rajagopalan K, Trueman D, Crowe L, Patel P, Loebel A. Cost-Utility and Budget Impact Analyses Comparing Lurasidone with Aripiprazole in Adults with Schizophrenia in Scotland. *Value Health.* 2015;18(7):A408-9.
5. Rajagopalan K, Trueman D, Crowe L, Patel P, Loebel A. Lurasidone in Adults with Schizophrenia in the UK: A Cost Consequence Analysis Considering Cost Implications of Improved Efficacy and Safety. *Value Health.* 2015;18(7):A408.
6. Murray G, Crowe L, Howells R. The Medical Technologies Evaluation Programme (MTEP): An Analysis Of Notifications, Decision-Making And The Interpretation Of Claimed Healthcare System Benefits. *Value Health.* 2015;18(7):A367.
7. Liu FX, Treharne C, Arici M, Crowe L, Culleton B. High-dose hemodialysis versus conventional in-center hemodialysis: a cost-utility analysis from a UK payer perspective. *Value Health.* 2015;18(1):17-24.
8. Ihara Z, Booth D, Treharne C, Crowe L. Benefits of the TURis system for transurethral resection of the prostate in benign prostatic hyperplasia: systematic review, meta-analysis and economic evaluation for England and Wales. *World Congress of Endourolog.* 2015.
9. Treharne C, Liu FX, Arici M, Crowe L, Farooqui U. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective. *Appl Health Econ Health Policy.* 2014;12(4):409-20.
10. Rajagopalan K, Trueman D, Crowe L, Pikalov A, Hsu J, Loebel A. Meta-analysis of drivers of cost-effectiveness from short-term lurasidone clinical trials: Effect of changing daily dose on PANSS total score and weight. *Value Health.* 2014;17(3):A208.
11. Liu FX, Treharne C, Culleton B, Crowe L, Arici M. The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis. *BMC Nephrol.* 2014;15:161.
12. Frappier J, Stanish W, Brittberg M, Steinwachs M, Crowe L, Castelo D, et al. Economic evaluation of BST-CarGel as an adjunct to microfracture vs microfracture alone in knee cartilage surgery. *J Med Econ.* 2014;17(4):266-78.
13. Liu FX, Treharne C, Lees L, Arici M, Culleton B. FR-PO341: High dose in-center hemodialysis and conventional in-center hemodialysis: A head-to-head cost-effectiveness analysis. *ASN Kidney Week, November.* 2013.
14. Liu FX, Treharne C, Culleton B, Arici M, Lees L. FR-PO340: High dose home hemodialysis and conventional in-center hemodialysis: A cost utility analysis. *ASN Kidney Week, November.* 2013.
15. Liu FX, Treharne C, Arici M, Lees L, Davis I, Sloand J. Peritoneal dialysis and in-centre haemodialysis: a cost-effectiveness analysis. *ASN Kidney Week, November.* 2012.
16. Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, et al. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. *Hum Vaccin Immunother.* 2012;8(3):312-22.